Omega-3 attenuates the severity of medication-related osteonecrosis of the jaws in rats treated with zoledronate

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(3), P. e0320413 - e0320413

Published: March 26, 2025

This study aimed to evaluate the ability of ω-3 modulate tissue response in rats with MRONJ, focusing on histopathological and immunohistochemical parameters. Forty Wistar were subjected bilateral ovariectomy and, three months later, medication regimen ZOL (100μg/kg; groups ZOL-ω3) vehicle (VEH VEH-ω3) was initiated. Following 3 weeks or VEH, experimental periodontitis induced around mandibular left first molars all animals. Then, 14 days later (one day before tooth extraction), daily dietary supplementation given animals belonging VEH-ω3 ZOL-ω3. Euthanasia performed 21 after extraction. Histologic, histometric (newly-formed bone [NFBT] non-vital [NVBT]), (TNF-α, α-SMA, ALP, IL-1β, VEGF, OCN, TRAP) analyses performed. Dietary reduced amount NVBT controlled intensity extension inflammatory infiltrate ZOL-ω3, as compared ZOL. Osteoclast osteoblast activity not statistically different between The structure epithelium underlining connective improved by under therapy. Oral omega-3 inflammation at extraction site ovariectomized treated attenuating severity MRONJ.

Language: Английский

Osteonecrosis of the jaw after radiation followed by bevacizumab

Dermatology Online Journal, Journal Year: 2024, Volume and Issue: 30(1)

Published: March 15, 2024

Osteonecrosis of the jaw is a recognized complication associated with bevacizumab. Here, we present patient squamous cell carcinoma tonsil who experienced minimal skin fibrosis following intensity-modulated radiation therapy. Subsequently, developed rectal adenocarcinoma and encountered osteonecrosis after receiving two cycles Close monitoring, accompanied by thorough examination to detect early signs jaw, should be considered for patients have undergone therapy in head neck region are bevacizumab or other medications known jaw.

Language: Английский